<?xml version="1.0" encoding="UTF-8"?>
<p id="Par121">The safety and efficacy of SABR as oligometastasis-directed treatment is increasingly being evaluated within prospective clinical trials. These data are awaited to compliment the abundance of existing observational studies and to guide clinical decision-making.</p>
